Clinical Drug Investigation

, Volume 14, Issue 1, pp 35–43 | Cite as

Pharmacokinetics and Pharmacodynamics of Interferon Beta-la (IFNβ-1a) in Healthy Volunteers after Intravenous, Subcutaneous or Intramuscular Administration

  • John Alam
  • Arthur McAllister
  • James Scaramucci
  • Wendy Jones
  • Mark Rogge
Pharmacology

Summary

The objective of this study was to define the single-dose pharmacokinetics and pharmacodynamics of interferon beta-la (IFNβ-1a) after various routes of administration. Three groups, each consisting of 8 healthy male and female subjects, received a single 60μg (12 million units) dose of IFNβ-1a by either a 30-minute intravenous infusion, or by subcutaneous or intramuscular injection. Serum interferon activity levels peaked immediately after the end of the intravenous infusion and thereafter fit a bioexponential decay model. The mean distribution and elimination half-lives were 4 minutes and 4 hours, respectively. The mean volume of distribution of the central compartment was 61.6L and the mean total clearance was 334 ml/h/kg. Interferon activity was consistently detectable in serum after intramuscular injection but not after subcutaneous injection. After intramuscular injection, peak serum interferon activity levels were approximately 40 U/ml and occurred 12 to 18 hours post-administration. The area under the curve for serum interferon activity was 2- to 3-fold higher after intramuscular injection than after subcutaneous injection. The pharmacodynamic response, as measured by changes in serum neopterin and β2-microglobulin concentrations, was also greatest after intramuscular injection, followed by subcutaneous, then intravenous administration. These results indicate that the optimal pharmacokinetic response is produced by intramuscular, rather than subcutaneous or intravenous, administration of IFNβ-1a.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alam J. Interferon-β treatment of human disease. Curr Op Biotech 1995; 6: 688–91CrossRefGoogle Scholar
  2. 2.
    Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39(3): 285–94PubMedCrossRefGoogle Scholar
  3. 3.
    Goodkin DE. Interferon beta-1b. Lancet 1994; 344: 1057–60PubMedCrossRefGoogle Scholar
  4. 4.
    Borden EC, Hawkins MJ, Sielaff KM, et al. Clinical and biological effects of recombinant interferon-β administered intravenously daily in phase I trial. J Interfer Res 1988; 8: 357–66CrossRefGoogle Scholar
  5. 5.
    Chiang J, Gloff CA, Yoshizawa CN, et al. Pharmacokinetics of recombinant human interferon-βser in healthy volunteers and its effect on serum neopterin. Pharm Res 1993; 10: 557–67CrossRefGoogle Scholar
  6. 6.
    Sarna G, Pertcheck M, Figlin R, et al. Phase I study of recombinant β ser 17 interferon in the treatment of cancer. Cancer Treat Rep 1986; 70(12): 1365–72PubMedGoogle Scholar
  7. 7.
    Hawkins M, Horning S, Konrad M, et al. Phase I evaluation of a synthetic mutant of β-interferon. Cancer Res 1985; 45: 5914–20PubMedGoogle Scholar
  8. 8.
    Hawkins MJ, Krown SE, Krim ECBM, et al. American cancer society phase I trial of naturally produced β-interferon. Cancer Res 1984; 44: 5934–8PubMedGoogle Scholar
  9. 9.
    Treuner J, Dannecker G, Joester K-E, et al. Pharmacological aspects of clinical stage I/II trials with human beta interferon in children. J Interfer Res 1981; 1(3): 373–80CrossRefGoogle Scholar
  10. 10.
    Liberati AM, Biscottini B, Fizzotti M, et al. A phase I study of human natural interferon-β in cancer patients. J Interfer Res 1989; 9: 339–48CrossRefGoogle Scholar
  11. 11.
    Witt PL, Storer BE, Bryan GT, et al. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-β. J Immunother 1993; 13: 191–200CrossRefGoogle Scholar
  12. 12.
    Goldstein D, Sielaff KM, Storer BE, et al. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-β serine. J Natl Cancer Inst 1989; 81(14): 1061–8PubMedCrossRefGoogle Scholar
  13. 13.
    Chiang J, Gloff CA, Soike KF, et al. Pharmacokinetics and antiviral activity of recombinant human interferon-βser in African green monkeys. J Interfer Res 1993; 13: 111–20CrossRefGoogle Scholar
  14. 14.
    WHO ExpertCommittee of Biological Standardisation. 38th World Health Organization Technical Report, Series 771, 1988; 36-8Google Scholar
  15. 15.
    Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, 1982Google Scholar
  16. 16.
    Liberati AM, Horisberger MA, Palmisano L, et al. Double-blind randomised phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-β. J Interfer Res 1992; 12: 329–36CrossRefGoogle Scholar
  17. 17.
    Salmon P, LeCotonnec J-Y, Galazka A, et al. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J Interferon Cyto Res 1996; 16: 759–64CrossRefGoogle Scholar
  18. 18.
    Paulesu L, Pessina GP, Bocci V. Human β-interferon incubated with muscle homogenate is protected by albumin but not by proteinase inhibitors. Proc Soc Exp Biol Med 1992; 200: 414–7PubMedGoogle Scholar
  19. 19.
    Avonex™ and Betaseron® Product Information, 1997: Physician’s Desk ReferenceGoogle Scholar
  20. 20.
    Welling PG. Pharmacokinetics. Washington: American Chemical Society, 1986Google Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • John Alam
    • 1
  • Arthur McAllister
    • 1
  • James Scaramucci
    • 1
  • Wendy Jones
    • 1
  • Mark Rogge
    • 1
  1. 1.Medical Research, Bioassay and Preclinical Development DepartmentsBiogen Inc.MassachusettsUSA

Personalised recommendations